Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study

Gastroenterology. 2020 Feb;158(3):527-536.e7. doi: 10.1053/j.gastro.2019.10.019. Epub 2019 Oct 22.

Abstract

Background & aims: Nearly all studies of gastric adenocarcinoma in the United States have relied on national cancer databases, which do not include data on Helicobacter pylori infection, the most well-known risk factor for gastric cancer. We collected data from a large cohort of patients in the United States to calculate the incidence of and risk factors for nonproximal gastric adenocarcinomas after detection of H pylori. Secondary aims included identifying how treatment and eradication affect cancer risk.

Methods: We performed a retrospective cohort study, collecting data from the Veterans Health Administration on 371,813 patients (median age 62 years; 92.3% male) who received a diagnosis of H pylori infection from January 1, 1994, through December 31, 2018. The primary outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylori infection. We performed a time to event with competing risk analysis (with death before cancer as a competing risk).

Results: The cumulative incidence of cancer at 5, 10, and 20 years after detection of H pylori infection was 0.37%, 0.5%, and 0.65%, respectively. Factors associated with cancer included older age at time of detection of H pylori infection (subhazard ratio [SHR], 1.13; 95% confidence interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), Asian race (SHR, 2.52; 95% CI, 1.64-3.89) (P < .001 for race), Hispanic or Latino ethnicity (SHR, 1.59; 95% CI, 1.34-1.87; P < .001), and history of smoking (SHR, 1.38; 95% CI, 1.25-1.52; P < .001). Women had decreased risk of gastric adenocarcinoma compared with men (SHR, 0.52; 95% CI, 0.40-0.68; P < .001); patients whose H pylori infection was detected based on serum antibody positivity also had a reduced risk of cancer (SHR 0.74; 95% CI, 0.54-1.04; P = .04). Patients who received treatment for their H pylori infection still had an increased risk of gastric cancer (SHR, 1.16; 95% CI, 0.74-1.83; P = .51) but confirmed H pylori eradication after treatment reduced risk of gastric cancer (SHR, 0.24; 95% CI, 0.15-0.41; P < .001).

Conclusions: In a study of 371,813 veterans with a diagnosis of H pylori infection, we found significantly higher risks of gastric cancer in racial and ethnic minorities and smokers. Treatment of H pylori infection decreased risk only if eradication was successful. Studies are needed on the effects of screening high-risk persons and to identify quality measures for diagnosis, resistance patterns, and treatment efficacy.

Keywords: Antibacterial Therapy; Microbe; Screening; Stomach Cancer.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma / epidemiology*
  • Adenocarcinoma / etiology
  • Adenocarcinoma / prevention & control
  • Age Factors
  • Aged
  • Antacids / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Drug Therapy, Combination / methods
  • Ethnicity / statistics & numerical data
  • Female
  • Follow-Up Studies
  • Health Status Disparities
  • Helicobacter Infections / complications
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / epidemiology*
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Proton Pump Inhibitors / therapeutic use
  • Race Factors
  • Retrospective Studies
  • Risk Factors
  • Smoking / adverse effects
  • Smoking / epidemiology
  • Stomach Neoplasms / epidemiology*
  • Stomach Neoplasms / etiology
  • Stomach Neoplasms / prevention & control
  • Time Factors
  • United States / epidemiology
  • United States Department of Veterans Affairs / statistics & numerical data
  • Veterans / statistics & numerical data

Substances

  • Antacids
  • Anti-Bacterial Agents
  • Proton Pump Inhibitors